Asensus Surgical (NYSE:ASXC) announced today that a Swiss hospital initiated a program with the Senhance robotic surgical system.
Inselspital, University Hospital Bern, Switzerland initiated its Senhance surgical system program, marking the second of two new agreements with two European hospitals in 2021, according to a news release. The university’s department of visceral surgery is implementing the digital platform in their daily surgical practice with plans to study its clinical utility over the coming months.
Senhance, touted as a first-of-its-kind digital laparoscopic platform, uses augmented intelligence to offer strong performance and patient outcomes through machine learning. Surgical assistance with the Senhance system includes haptic feedback, eye-tracking camera control and 3D visualization.
“Inselspital University Hospital in Bern is the largest University hospital group in Switzerland,” Asensus Surgical president & CEO Anthony Fernando said in the release. “We are very pleased they have started surgery with Senhance this week.’’
Research Triangle Park, N.C.-based Asensus (formerly TransEnterix) in February announced that the company would change its name from TransEnterix to Asensus Surgical and introduce a new surgery category with the aim of entering a new era of performance-guided surgery focused on digitizing the interface between surgeons and patients to bring clinical intelligence that may enable better outcomes and, potentially, a new standard of surgery.
